SCHEMBL4427769

SCHEMBL4427769

COc1ccccc1OCCCl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 6/20 0.59
TDP1 Q9NUW8 2/20 0.58
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA4 P22748 1/20 0.56
CA7 P43166 1/20 0.56
CA9 Q16790 1/20 0.56
CA14 Q9ULX7 1/20 0.56
LMNA P02545 3/20 0.56
MIF P14174 1/20 0.53
MAPT P10636 4/20 0.53
ALDH1A1 P00352 3/20 0.53
HPGD P15428 3/20 0.53
MAPK1 P28482 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.51
MTNR1A P48039 1/20 0.51
MTNR1B P49286 1/20 0.51
POLB P06746 1/20 0.50
HTR1A P08908 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30960112 1.00 L3MBTL1 (0.59) L3MBTL1TDP1CA12CA1CA2
SCHEMBL1545294 0.91 L3MBTL1 (0.63) L3MBTL1TDP1CA12CA1CA2
Water SCHEMBL10556855 0.89 L3MBTL1 (0.61) L3MBTL1TDP1CA12CA1CA2
SCHEMBL5659890 0.89 L3MBTL1 (0.67) L3MBTL1TDP1CA12CA1CA2
SCHEMBL6848695 0.89 KDM4E (0.54) L3MBTL1TDP1LMNAMAPTALDH1A1
SCHEMBL30862625 0.88 L3MBTL1 (0.72) L3MBTL1TDP1CA12CA1CA2
SCHEMBL9547466 0.88 L3MBTL1 (0.65) L3MBTL1TDP1CA12CA1CA2
SCHEMBL1592409 0.86 CA12 (0.68) L3MBTL1TDP1CA12CA1CA2
SCHEMBL29742293 0.84 L3MBTL1 (0.70) L3MBTL1TDP1CA12CA1CA2
SCHEMBL29742239 0.84 L3MBTL1 (0.77) L3MBTL1TDP1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009128088-A2 PREPARATION OF 2-(2-ALKOXY PHENOXY) ETHYLAMINE, AN INTERMEDIATE OF CARVEDILOL AND TAMSULOSIN SHODHANA LABORATORIES LIMITED (IN) 2009-10-22 WO claimed
WO-2009116069-A2 PROCESS FOR PREPARATION OF 1-(9H-CARBAZOL-4-YLOXY)-3-[[2-(2- METHOXYPHENOXY) ETHYL] AMINO]-2-PROPANOL IPCA LABORATORIES LIMITED (IN) 2009-09-24 WO claimed
CN-113861047-B Synthesis method of 2- (2-methoxyphenoxy) ethylamine 杭州国瑞生物科技有限公司 2024-05-14 CN disclosed
CN-113861047-A Synthetic method of 2- (2-methoxyphenoxy) ethylamine 杭州国瑞生物科技有限公司 2021-12-31 CN disclosed
CN-106146450-B Formoononetin derivative, preparation method and medical usage 南京华迈生物医药科技有限公司 2019-02-15 CN disclosed
CN-109206328-A A kind of preparation method of 2- (2- methoxyphenoxy) ethamine 铜仁学院 2019-01-15 CN disclosed
CN-109206328-A A kind of preparation method of 2- (2- methoxyphenoxy) ethamine 铜仁学院 2019-01-15 CN disclosed
CN-106146450-A Formoononetin derivant, its preparation method and medical usage 南京华迈生物医药科技有限公司 2016-11-23 CN disclosed
US-20150057272-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2015-02-26 US disclosed
WO-2012111020-A1 PYRROLO [2,1-C]1,4]NAPHTHODIAZEPINE LINKED PIPERAZINE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2012-08-23 WO disclosed
US-20110124637-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-05-26 US disclosed
WO-2002048105-A2 ARYLOXY PIPERIDINYL DERIVATIVES FOR THE TREATMENT OF DEPRESSION WYETH (US) 2002-06-20 WO disclosed
US-20010051620-A1 Tricyclic protein kinase inhibitors AMERICAN HOME PRODUCTS CORPORATION (US) 2001-12-13 US disclosed
EP-1123933-A1 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane as CNS active agent MERCK PATENT GmbH (DE) 2001-08-16 EP disclosed
WO-2001047892-A1 TRICYCLIC PROTEIN KINASE INHIBITORS WYETH (US) 2001-07-05 WO disclosed
EP-0823659-B1 Negative type image recording material FUJI PHOTO FILM CO LTD (JP) 1999-12-01 EP disclosed
US-5948590-A CAPABLE OF PROCESSING DIRECTLY FROM COMPUTER AND OTHER DIGITAL DATA, WITH EXCELLENT PRINTING DURABILITY AT THE TIME OF PRINTING AND LACK OF STAINING. POLYMER, CURING AGENT, COMPOUND WHICH GENERATES AN ACID IN PRESENCE OF HEAT OR LIGHT. FUJI PHOTO FILM CO., LTD. (JP) 1999-09-07 US disclosed
US-5767132-A CENTRAL NERVOUS SYSTEM MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1998-06-16 US disclosed
EP-0823659-A1 Negative type image recording material FUJI PHOTO FILM CO., LTD. (JP) 1998-02-11 EP disclosed
EP-0707007-A1 Amino(thio)ether derivatives as CNS active agents MERCK PATENT GmbH (DE) 1996-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051620-A1 Tricyclic protein kinase inhibitors CDK1, CHEK1, ABL1 L3MBTL1 2151/4885TDP1 428/4885CA12 4754/4885
US-20110124637-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 L3MBTL1 3042/4885TDP1 1438/4885CA12 4866/4885
US-20150057272-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 L3MBTL1 1805/4885TDP1 1272/4885CA12 4869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.